Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Июль 31, 2024
Diabetic
kidney
disease
(DKD)
is
one
of
the
leading
causes
end-stage
renal
worldwide
and
significantly
increases
risk
premature
death
due
to
cardiovascular
diseases.
Elevated
urinary
albumin
levels
are
an
important
clinical
feature
DKD.
Effective
control
albuminuria
not
only
delays
glomerular
filtration
rate
decline
but
also
markedly
reduces
all-cause
mortality.
New
drugs
for
treating
DKD
proteinuria,
including
sodium-glucose
cotransporter
two
inhibitors,
mineralocorticoid
receptor
antagonists,
endothelin
have
shown
significant
efficacy.
Auxiliary
treatment
with
proprietary
Chinese
medicine
has
yielded
promising
results;
however,
it
faces
a
broader
scope
development.
The
mechanisms
by
which
these
treat
in
patients
should
be
described
more
thoroughly.
positive
effects
combination
therapy
or
reducing
protecting
kidneys
warrant
further
investigation.
Therefore,
this
review
explores
pathophysiological
mechanism
DKD,
value
diagnosis
prognosis,
new
progress
treatment,
multidrug
who
type
2
diabetic
disease,
providing
perspective
on
Abstract
Background
Polypharmacy
would
increase
the
risk
of
adverse
drug
events
and
burden
renal
excretion
among
older
people.
Nevertheless,
association
between
number
medication
chronic
kidney
disease
(CKD)
remains
controversial.
Therefore,
this
study
aims
to
investigate
incidence
CKD
in
Methods
This
investigates
medications
2672
elderly
people
(≥
65
years
older)
community
health
service
center
southern
China
2019
2022.
Logistic
regression
analysis
was
used
evaluate
relationship
polypharmacy
CKD.
Results
At
baseline,
average
age
subjects
71.86
±
4.60,
61.2%
were
females,
53
(2.0%)
suffer
from
polypharmacy.
During
an
follow-up
3
years,
new-onset
developed
413
(15.5%)
participants.
revealed
that
taking
a
higher
associated
with
Compared
who
didn’t
take
medication,
observed
taken
more
than
five
(OR
3.731,
95%
CI
1.988,
7.003),
followed
by
those
four
1.621,
1.041,
2.525),
three
1.696,
1.178,
2.441),
two
drugs
1.585,
1.167,
2.153),
or
one
1.503,
1.097,
2.053).
Furthermore,
age,
systolic
blood
pressure
(SBP),
white
cell
(WBC),
urea
nitrogen
(BUN)
triglyceride
(TG)
also
independent
factors
(
P
<
0.05).
Conclusion
The
As
increased,
increased.
Chonnam Medical Journal,
Год журнала:
2020,
Номер
56(3), С. 157 - 157
Опубликована: Янв. 1, 2020
Antipsychotics
have
been
utilized
as
the
standard
treatment
for
schizophrenia
regardless
of
illness
phase
where
antipsychotic
monotherapy
(APM)
is
routinely
recommended
gold
rather
than
polypharmacy
(APP).
However,
approximately
20
to
40%
patients
with
do
not
respond
APM
based
on
randomized
controlled
clinical
trials
and
large
practical
indicating
that
subgroup
would
need
differential
approaches
beyond
traditional
strategies
such
APM.
Numerous
studies
supported
use
APP
in
particular
certain
situations
including:
failure
show
efficacy
or
tolerability
from
APM,
different
targeting
specific
symptom
domains,
severe
illness,
clozapine,
skepticism
about
following
guidelines,
cross
titration
periods.
Furthermore,
recent
cohort
proposed
more
benefits
terms
rehospitalization,
mortality,
symptoms.
has
recently
become
widely
recognized
one
next
clinicians
schizophrenia.
Some
experts
already
revision
guidelines
incorporating
evidence-based
option
Taken
together,
now
deserves
an
acceptable
strategy,
empirical
preferential
approach
contemporary
practice.
Clinical Interventions in Aging,
Год журнала:
2023,
Номер
Volume 18, С. 1129 - 1143
Опубликована: Июль 1, 2023
Deprescribing
is
essential
for
reducing
inappropriate
medication
use
and
polypharmacy.
For
a
holistic
approach,
it
to
know
how
older
adult
patients
their
caregivers
perceive
deprescribing.To
assess
the
attitude
of
towards
deprescribing
at
Ambo
University
Referral
Hospital.Institutional-based
cross-sectional
study
was
conducted
using
revised
Patients'
Attitude
Towards
tool
(rPATD).
The
data
analyzed
SPSS-25
software.
Backward
linear
regression
logistic
were
used
measure
association
between
outcome
determinant
variables.
two-sided
P-value
≤0.05
with
95%
confidence
interval
utilized
reporting
significant
factors.One
hundred
fifty-six
(81.3%)
respondents
(ie,
85.0%
77.2%
caregivers)
agreed
stop
one
or
more
regular
medications
if
physician
said
possible
despite
98
(51.0%)
them
49.0%
53.3%
being
satisfied
their/their
care
recipient's
medications.
On
overall
aggregate
mean
score,
had
neutral
position
(2.6-3.59)
regarding
burden
concerns
stopping
whereas
majority
disagree
(1.0-2.59)
inappropriateness
they
taking
(3.6-5.0)
need
involvement
in
treatment
decision
making.
Concerns
about
medicine
scores
(AOR
=
0.440,
CI
0.262-0.741,
P
0.035)
perceived
levels
0.653,
0.456-0.936,
0.020)
significantly
associated
willingness
discontinue
satisfaction
regimen
respectively.The
would
like
deprescribe
physicians
recommended
it.
medicines
respectively.
Healthcare
providers
should
prompt
process
by
addressing
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Июль 31, 2024
Diabetic
kidney
disease
(DKD)
is
one
of
the
leading
causes
end-stage
renal
worldwide
and
significantly
increases
risk
premature
death
due
to
cardiovascular
diseases.
Elevated
urinary
albumin
levels
are
an
important
clinical
feature
DKD.
Effective
control
albuminuria
not
only
delays
glomerular
filtration
rate
decline
but
also
markedly
reduces
all-cause
mortality.
New
drugs
for
treating
DKD
proteinuria,
including
sodium-glucose
cotransporter
two
inhibitors,
mineralocorticoid
receptor
antagonists,
endothelin
have
shown
significant
efficacy.
Auxiliary
treatment
with
proprietary
Chinese
medicine
has
yielded
promising
results;
however,
it
faces
a
broader
scope
development.
The
mechanisms
by
which
these
treat
in
patients
should
be
described
more
thoroughly.
positive
effects
combination
therapy
or
reducing
protecting
kidneys
warrant
further
investigation.
Therefore,
this
review
explores
pathophysiological
mechanism
DKD,
value
diagnosis
prognosis,
new
progress
treatment,
multidrug
who
type
2
diabetic
disease,
providing
perspective
on
